Immunotech Biopharm Ltd (6978.HK)
HKD 2.47
(8.33%)
HKD 2.47
(8.33%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -163.62 Million | -180.92 Million | -254.65 Million | -263.66 Million | -95.46 Million | -44.07 Million |
| Net Income | -335.47 Million | -321.09 Million | -354.61 Million | -439.12 Million | -109.05 Million | -34.88 Million |
| Depreciation & Amortization | 53.39 Million | 44.07 Million | 21 Million | 13.78 Million | 10.94 Million | 4.51 Million |
| Deferred income taxes | - | - | 17.71 Million | 23.73 Million | -5.76 Million | - |
| Stock-based compensation | - | 4.28 Million | 48.94 Million | 151.7 Million | 405 Thousand | 405 Thousand |
| Change in working capital | 12.3 Million | 45.09 Million | 19.07 Million | -29.34 Million | 3.3 Million | -8.95 Million |
| Other non-cash items | -377 Thousand | 46.72 Million | -6.77 Million | 15.58 Million | 4.69 Million | -4.75 Million |
| Investing Cash Flow | -116.59 Million | 23.38 Million | -328.2 Million | -204.06 Million | 25.74 Million | -50.4 Million |
| Investments in PPE | -22.53 Million | -96.56 Million | -181.23 Million | -75.67 Million | -21.02 Million | -35.07 Million |
| Acquisitions | - | - | - | - | - | 19.58 Million |
| Investment purchases | -100 Million | -152.02 Million | -150.08 Million | -131.96 Million | - | -50 Million |
| Sales/Maturities of investments | - | 230.08 Million | - | - | 46.77 Million | 14.89 Million |
| Other Investing Activities | 2.17 Million | 41.89 Million | 3.11 Million | 3.57 Million | -13 Thousand | 183 Thousand |
| Financing Cash Flow | 273.92 Million | -36.06 Million | -10.99 Million | 1.05 Billion | 217.2 Million | 214.44 Million |
| Debt repayment | -299 Million | -17.43 Thousand | -7321.00 | -4476.00 | -2883.00 | -2204.00 |
| Dividends payments | - | - | - | - | -929 Thousand | -33.56 Million |
| Common Stock Repurchased | - | - | - | - | -6.81 Million | - |
| Common Stock Issuance | - | - | - | 1.13 Billion | 2883.00 | - |
| Other Financing Activities | -8.51 Million | -36.04 Million | -10.99 Million | -82.41 Million | 224.95 Million | 248.01 Million |
| Accounts receivables | 256 Thousand | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | 2.28 Million | 3.65 Million | -6.89 Million | 835 Thousand | -2.51 Million | -1.66 Million |
| Other working capital | 6.63 Million | 41.44 Million | 25.96 Million | -30.18 Million | 5.82 Million | -7.28 Million |
| Cash at beginning of period | 58.44 Million | 251.4 Million | 845.38 Million | 282.24 Million | 128.33 Million | 3.39 Million |
| Cash at end of period | 52.16 Million | 58.44 Million | 251.4 Million | 845.38 Million | 282.24 Million | 128.33 Million |
| Capital Expenditure | -22.53 Million | -96.56 Million | -181.23 Million | -75.67 Million | -21.02 Million | -35.07 Million |
| Effect of forex changes on cash | 17 Thousand | 648 Thousand | -127 Thousand | -23.81 Million | 6.43 Million | 4.97 Million |
| Net cash flow / Change in cash | -6.28 Million | -192.95 Million | -593.98 Million | 563.13 Million | 153.91 Million | 124.94 Million |
| Free Cash Flow | -186.16 Million | -277.48 Million | -435.89 Million | -339.33 Million | -116.49 Million | -79.14 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -46.25 Thousand | -46.25 Thousand | -335.47 Million | -108.35 Thousand | -108.35 Thousand | -59.05 Thousand |
| Depreciation & Amortization | 15.18 Thousand | 15.18 Thousand | 53.39 Million | 13.61 Thousand | 13.02 Thousand | 13.08 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | 12.3 Million | 4461.50 | 4461.50 | - |
| Other non-cash items | -8689.50 | -8689.50 | -377 Thousand | 52.88 Thousand | 53.47 Thousand | 1553.00 |
| Investing Cash Flow | 58.83 Thousand | 58.83 Thousand | -116.59 Million | 2867.00 | 2867.00 | -61.16 Thousand |
| Investments in PPE | -9825.00 | -9825.00 | -22.53 Million | -3478.00 | -3478.00 | -6311.50 |
| Acquisitions | - | - | - | - | - | 927.38 Thousand |
| Investment purchases | - | - | -100 Million | - | - | -266.74 Million |
| Sales/Maturities of investments | - | - | - | - | - | 142.42 Million |
| Other Investing Activities | 68.65 Thousand | 68.65 Thousand | 2.17 Million | 6345.00 | 6345.00 | -54.85 Thousand |
| Financing Cash Flow | -5338.50 | -5338.50 | 273.92 Million | -6293.50 | -6293.50 | 143.25 Thousand |
| Debt repayment | - | - | -299 Million | - | - | -339.28 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -5338.50 | -5338.50 | -8.51 Million | -6293.50 | -6293.50 | 143.25 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | 2.28 Million | 1144.50 | 1144.50 | - |
| Other working capital | - | - | 6.63 Million | 3317.00 | 3317.00 | - |
| Cash at beginning of period | -0.50 | - | 58.44 Million | - | - | 65.62 Million |
| Cash at end of period | 13.74 Thousand | 13.74 Thousand | 52.16 Million | -40.78 Thousand | -40.78 Thousand | 145.2 Million |
| Capital Expenditure | -9825.00 | -9825.00 | -22.53 Million | -3478.00 | -3478.00 | -6311.50 |
| Effect of forex changes on cash | 4.00 | 4.00 | 17 Thousand | 32.50 | 32.50 | -24.00 |
| Net cash flow / Change in cash | 13.74 Thousand | 13.74 Thousand | -6.28 Million | -40.78 Thousand | -40.78 Thousand | 79.58 Million |
| Free Cash Flow | -49.58 Thousand | -49.58 Thousand | -186.16 Million | -40.87 Thousand | -40.87 Thousand | -50.73 Thousand |
CDNIF
108675
4972
FMCC
000543
KSC